Halozyme Therapeutics (HALO) Current Assets (2010 - 2026)

Halozyme Therapeutics (HALO) has 17 years of Current Assets data on file, last reported at $1.0 billion in Q1 2026.

• On a quarterly basis, Current Assets fell 20.52% year-over-year to $1.0 billion in Q1 2026; TTM through Mar 2026 was $1.0 billion, a 20.52% decrease from a year earlier, with the FY2025 full-year figure at $825.2 million, down 23.97% from the prior year.
• Current Assets for Q1 2026 stood at $1.0 billion, up from $825.2 million in the prior quarter.
• Over the last five years, Current Assets for HALO reached as high as $1.3 billion in Q3 2025 and fell as low as $541.9 million in Q2 2022.
• Historically, Current Assets has averaged $914.4 million across 5 years, with a median of $879.0 million in 2023.
• Across the five-year window, Current Assets plunged 45.79% in 2022 and surged 45.41% in 2024, its largest moves.
• Year by year, Current Assets stood at $739.0 million in 2022, then climbed by 1.0% to $746.4 million in 2023, then jumped by 45.41% to $1.1 billion in 2024, then dropped by 23.97% to $825.2 million in 2025, then climbed by 21.55% to $1.0 billion in 2026.
• Per Business Quant data, the three most recent Current Assets figures were $1.0 billion in Q1 2026, $825.2 million in Q4 2025, and $1.3 billion in Q3 2025.